𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biomarkers for apoptosis in Alzheimer's disease

✍ Scribed by Maria Ankarcrona; Bengt Winblad


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
85 KB
Volume
20
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Alzheimer's disease (AD) affects millions of people worldwide and the number of AD cases will increase with increased life expectancy. Today there is no cure for this devastating and always lethal disease and therefore it is of great interest for patients, relatives and societies to find new drugs that can hinder the disease process. During the progression of AD a substantial amount of neurons degenerate in the brain. The mechanisms of cell death involved in AD have not been fully elucidated. However, there are several reports showing that neurons die partly by apoptosis in the AD brain. Drugs blocking apoptosis could therefore be potentially useful for early prevention of neuronal cell death. Biomarkers for apoptosis should be important tools in the evaluation of drug effects and in the diagnostics of AD. Here we review the current knowledge in the field and discuss potential biomarkers for apoptosis in AD. Copyright Β© 2005 John Wiley & Sons, Ltd.


πŸ“œ SIMILAR VOLUMES


Ventricular shape biomarkers for Alzheim
✍ Luca Ferrarini; Walter M. Palm; Hans Olofsen; Roald van der Landen; Mark A. van πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 466 KB

## Abstract The aim of this work was to identify ventricular shape‐based biomarkers in MR images to discriminate between patients with Alzheimer's disease (AD) and healthy elderly. Clinical MR images were collected for 58 patients and 28 age‐matched healthy controls. After normalizing all the image

Structural MRI biomarkers for preclinica
✍ Christine Fennema-Notestine; Donald J. Hagler Jr.; Linda K. McEvoy; Adam S. Flei πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 535 KB

## Abstract Noninvasive MRI biomarkers for Alzheimer's disease (AD) may enable earlier clinical diagnosis and the monitoring of therapeutic effectiveness. To assess potential neuroimaging biomarkers, the Alzheimer's Disease Neuroimaging Initiative is following normal controls (NC) and individuals w